8-K current report · filed Sep 15, 2026

Biomarin Pharmaceutical Inc (BMRN) 8-K Current Report: September 15, 2026

Item 8.01BMRN overview

Short answer

Biomarin Pharmaceutical Inc (BMRN) filed an 8-K current report with the SEC on September 15, 2026 reporting Item 8.01 (Other Events). BioMarin discontinued VOXZOGO development for children with Noonan syndrome.

Biomarin Pharmaceutical Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • BioMarin discontinued VOXZOGO development for children with Noonan syndrome
  • Decision reflects study feasibility and the existing treatment landscape
  • Discontinuation was not related to VOXZOGO safety or efficacy
  • Strategic impact: reduced expansion opportunity for VOXZOGO in Noonan syndrome, without a disclosed product safety setback

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Biomarin Pharmaceutical Inc 8-K filings

Get the next BMRN 8-K as it lands

Follow BMRN for push alerts, or ask the research agent what this filing means.